EVI2B抗体;EVI2B Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13358(EVI2B Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13358(EVI2B Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

EVI2B (Ecotropic Viral Integration Site 2B) is a gene located on human chromosome 7q22.1. initially identified due to its association with retroviral integration sites in myeloid leukemia. The EVI2B protein, a transmembrane glycoprotein, belongs to the proteoglycan family and is characterized by multiple membrane-spanning domains and glycosaminoglycan (GAG) attachment sites. It is predominantly expressed in hematopoietic cells, particularly myeloid lineages, and has been implicated in cellular processes such as cell adhesion, proliferation, and immune regulation. Dysregulation of EVI2B is linked to malignancies, notably acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), where its overexpression may contribute to oncogenic signaling pathways.

Antibodies targeting EVI2B are primarily utilized in research to study its expression patterns, subcellular localization, and functional roles in normal and pathological contexts. These antibodies enable detection via techniques like Western blotting, flow cytometry, and immunohistochemistry, aiding in the exploration of EVI2B's interaction with signaling molecules (e.g., JAK-STAT or PI3K/AKT pathways) and its potential as a diagnostic or therapeutic biomarker. Recent studies also suggest EVI2B's involvement in modulating EGFR trafficking, further expanding its relevance in cancer biology. Despite its unclear exact mechanistic role, EVI2B remains a subject of interest in hematopoiesis and oncology research, with antibodies serving as critical tools to unravel its biological and clinical significance.